Status:
COMPLETED
Sequence of Radiation and Targeted Therapy in Brain Metastases
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
The Optimal Sequence of Radiotherapy and Systematic Tyrosine Kinase Inhibitors in Treating Brain Metastases
Eligibility:
All Genders
18-80 years
Brief Summary
The investigators conducted a single institutional, retrospective cohort study to demonstrate the appropriate treatment strategy of upfront intracranial radiotherapy or upfront targeted therapy in pat...
Eligibility Criteria
Inclusion
- Had histologically proven primary cancer.
- Had newly diagnosed brain metastases in contrast-enhanced MRI.
- Brain metastases focus should be measurable.
- All the patients should safely receive radiotherapy and/or systematic tyrosine kinase inhibitors.
- Karnofsky performance score (KPS) ≥60 or KPS ≥40, but only caused by brain metastases.
Exclusion
- Patients with prior intracranial local treatments, such as surgery and radiotherapy without dose prescription in detail
- Patients with leptomeningeal metastases at first diagnosis.
- Had synchronous or metachronous malignancies that might affect survival.
- Had severe systemic diseases, abnormal conditions that might lead to incoordinate behavior during the implementation of clinical measures.
- Had incomplete sociodemographic and/or clinicopathologic baseline data
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2021
Estimated Enrollment :
570 Patients enrolled
Trial Details
Trial ID
NCT04832672
Start Date
October 1 2010
End Date
March 1 2021
Last Update
April 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021